A 10-hour course for educators creates a common language for teaching phonemic awareness across all grade levels.

Google released the December 2025 core update today, the company announced. This is the third core update of 2025 and the fourth major Google algorithm update overall. Earlier this year, Google rolled ...

Praxis Precision Medicines, Inc. surged 35% after EMBOLD study success and strong pipeline progress, reaching its highest valuation since early 2022. PRAX's relutrigine and ulixacaltamide both ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10. Check out the current price of PRAX stock here. PRAX closed Thursday's regular ...

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

A record 77.3% of Mississippi third graders passed their initial reading assessment in spring 2025. The total pass rate, including retests, reached 84.6%, a slight increase from the previous school ...

Scala Data Centers in partnership with Lightera and Nokia completed Latin America’s first successful test of hollow core fiber (HCF) technology in what the companies claim is a game changer for the ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. What’s going on? This debate over ...

Ten months ago, Google said on stage at Google Search Central Live event in the Google Zurich office that we should expect more core update, more update. We now have about two months left of the 2025 ...

Stephen Gorard receives funding from Economic and Social Research Council, and Department for Education, to conduct work in this general area. All secondary-age school pupils in year eight (aged 12 ...

Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...

Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...